Clinical Trials · NCT05870579
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 22
- Start date
- Nov 2023
- Locations
- 13 sites, 7 countries
- Primary endpoint
- Incidence and nature of DLTs during the DLT observation period